Organisation paid for research Program year 2024 Source: CMS Open Payments

Research By Design, LLC

Neither a doctor nor a teaching hospital

Research payments

$109,122

11 payments

Through program year 2024, Research By Design, LLC is reported as receiving $109,122 in research payments, across 11 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$11,356	1
2022	Research	$22,636	3
2021	Research	$3,085	6
2020	Research	$72,045	1

Breakdown

Who paid Research payments · program years 2020–2024

OPKO Pharmaceuticals, LLC $72,045 1 payment
Bayer HealthCare Pharmaceuticals Inc. $33,992 4 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $2,276 3 payments
Boehringer Ingelheim Limited $808 3 payments

Studies the money was for Research payments · program years 2020–2024

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI $72,045 1 payment
BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $22,636 3 payments
BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic $11,356 1 payment
BI 685509 Dose finding/PoCC in DKD $2,276 3 payments
BI 685509 Dose finding/PoCC in Non-Diabetic CKD $808 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.